Patents Assigned to TOPHARMAN SHANDONG CO., LTD.
-
Patent number: 10174011Abstract: The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.Type: GrantFiled: March 9, 2015Date of Patent: January 8, 2019Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANDONG CO., LTD.Inventors: Hualiang Jiang, Zhen Wang, Jianfeng Li, Rongxia Zhang, Yang He, Yongjian Liu, Minghao Bi, Zheng Liu, Guanghui Tian, Weiming Chen, Feipu Yang, Chunhui Wu, Yu Wang, Xiangrui Jiang, Jingjing Yin, Guan Wang, Jingshan Shen
-
Publication number: 20170158680Abstract: The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.Type: ApplicationFiled: March 9, 2015Publication date: June 8, 2017Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANDONG CO., LTD.Inventors: Hualiang JIANG, Zhen WANG, Jianfeng LI, Rongxia ZHANG, Yang HE, Yongjian LIU, Minghao BI, Zheng LIU, Guanghui TIAN, Weiming CHEN, Feipu YANG, Chunhui WU, Yu WANG, Xiangrui JIANG, Jingjing YIN, Guan WANG, Jingshan SHEN
-
Patent number: 9527849Abstract: The present invention relates to new salts of pyrazolopyrimidinone represented by formula (I), and pharmaceutically acceptable polymorph, solvate, hydrate, dehydrate, co-crystallization, anhydrous, or amorphous form thereof, the pharmaceutical compositions, and a pharmaceutical unit dosage form containing the same, wherein x represents organic or inorganic acids, preferable maleic acid, succinic acid, methanesulfonic acid, hydrochloric acid, etc. The invention further relates to co-crystals or complexes of compounds of pyrazolopyrimidinone and pharmaceutical compositions containing the same. The present invention also relates to a process for the preparation, use thereof and pharmaceutical preparation containing the salts or crystalline forms.Type: GrantFiled: August 14, 2012Date of Patent: December 27, 2016Assignees: TOPHARMAN SHANGHAI CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES TOPHARMAN SHANDONG CO., LTDInventors: Jianfeng Li, Guanghui Tian, Zhen Wang, Jin Suo, Xiangrui Jiang, Zheng Liu, Xiaojun Yang, Zhu Xie, Xianguo Zhao, Weiliang Zhu, Hualiang Jiang, Jingshan Shen
-
Patent number: 9376410Abstract: This invention disclose (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone in a single configuration and preparation method and use thereof. The (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone, or a pharmaceutically acceptable salt, an ester, a prodrug or a solvate thereof according to the invention are important intermediates of a variety of anti-viral and anti-tumor active ingredients. A compound obtained from (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone via an acylation reaction can be directly used for preparing various anti-viral and anti-tumor drugs. The Chiral synthesis method and the spontaneous resolution method of the compound of (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone according to the invention have the following advantages: the reaction routes are short and simple with high yield and low cost, which are suitable for industrial application.Type: GrantFiled: October 10, 2013Date of Patent: June 28, 2016Assignees: TOPHARMAN SHANGHAI CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, TOPHARMAN SHANDONG CO., LTD.Inventors: Guan Wang, Xiangrui Jiang, Xudong Gong, Weiming Chen, Fuqiang Zhu, Rongxia Zhang, Xianguo Zhao
-
Patent number: 8884021Abstract: Provided is a process for preparing racemic nicotine from 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof using one-pot process. The process comprises the following steps: 1) in a reaction vessel, reacting 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof in the presence of a suitable solvent and a strong acid by heat; after the reaction is complete, cooling the same and adjusting the pH to 7-8 with alkali; and 2) directly adding a reductant into the above vessel, and after the reaction, purifying the product so as to obtain high purity racemic nicotine or a salt thereof.Type: GrantFiled: January 20, 2012Date of Patent: November 11, 2014Assignees: Topharman Shanghai Co., Ltd., Topharman Shandong Co., Ltd.Inventors: Guanghui Tian, Guan Wang, Xiaoguang Kong, Rongxia Zhang, Weiming Chen, Jingshan Shen
-
Patent number: 8871777Abstract: The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like.Type: GrantFiled: December 10, 2009Date of Patent: October 28, 2014Assignees: Topharman Shanghai Co., Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Topharman Shandong Co., Ltd.Inventors: Zheng Liu, Jianfeng Li, Xiaojun Yang, Zhen Wang, Jinfeng Zhang, Yi Zhu, Guanghui Tian, Qing Jin, Jingkang Shen, Weiliang Zhu, Hualiang Jiang, Jingshan Shen
-
Publication number: 20140031554Abstract: Provided is a process for preparing racemic nicotine from 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof using one-pot process. The process comprises the following steps: 1) in a reaction vessel, reacting 1-methyl-3-nicotinoyl-2-pyrrolidone or a salt thereof in the presence of a suitable solvent and a strong acid by heat; after the reaction is complete, cooling the same and adjusting the pH to 7-8 with alkali; and 2) directly adding a reductant into the above vessel, and after the reaction, purifying the product so as to obtain high purity racemic nicotine or a salt thereof.Type: ApplicationFiled: January 20, 2012Publication date: January 30, 2014Applicants: TOPHARMAN SHANGHAI CO., LTD., TOPHARMAN SHANDONG CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Guanghui Tian, Guan Wang, Xiaoguang Kong, Rongxia Zhang, Weiming Chen, Jingshan Shen